Saturday, June 19, 2010
Can we all Possess Savant Like Skills?
My friend in New York sent me a link addressing the work of Alan Snyder who for many years has been arguing that within all of us reside hidden talents that can be unmasked through inhibiting certain regions of the brain. He goes so far as to state that this ability can constitute genius, more on that latter. While I have a number of problems with the various assumptions embedded in the ideas of Snyder and his team I also acknowledge that most laypeople operate from the same assumptions and as do many professionals. Nonetheless the perspective of Snyder may have utility and so in the spirit of "News ideas are like seedlings, easily trampled", let's play the game and see what we can learn ...
at
1:06 AM
Posted by
John
8
comments
Labels:
aspergers,
autism,
cognition,
creativity,
inhibition,
snyder
Thursday, June 10, 2010
Peter Carey You Pretentious Dumbass
Who are these dinosaurs who think they can determine the true measure of intelligence? At the Sydney Writers' Festival one of Australia's most prominent "literary novelists", Peter Carey, whines about how we are turning into a nation of idiots. As regards to the purported dumbing down of our culture I addressed that in this post. Peter Carey might want to learn something about the vagaries of statistical analyses the douchebag. He might also wish to remember that the earliest recorded instance of someone complaining about the younger generation goes back to the Assyrians.
Tuesday, June 8, 2010
New Targets for Anti-Depressants?
This post is very long (3850 words) and very difficult. It is a preliminary investigation of the idea that depression arises from chronic sustained arousal leading to amine depletion and various other physiological changes.
This news release from Science Daily highlights a new pharmacological approach to treating depression. The nutshell is this: there is a class of proteins in our brains called RGS proteins which inhibit the signalling of various neurotransmitters. By manipulating the RGS protein that inhibits serotonin signalling we can treat depression. Most current anti-depressant drugs attempt to increase the levels of serotonin or norepinephrine. Unfortunately there are now some studies emerging which indicate these current anti-depressants can increase the risk to develop a range of disorders, from kidney problems to cataracts. Generally the risk profiles are low but given the very widespread use of anti-depressants it could constitute a considerable public health cost. Which raises an interesting question: if we place our faith in these statistical analyses then is the government entitled to extract an "pharmaceutical externality tax" to address the health risks and subsequent costs associated with drug side effectss? Yeah, like that'll ever happen. We'll develop a new class of anti-depressants, and wait 30 years before we know about the associated risks ... .
My unalloyed cynicism aside, what caught my interest about this research is the reference to RGS proteins. It reminded me I read in 1999:
This news release from Science Daily highlights a new pharmacological approach to treating depression. The nutshell is this: there is a class of proteins in our brains called RGS proteins which inhibit the signalling of various neurotransmitters. By manipulating the RGS protein that inhibits serotonin signalling we can treat depression. Most current anti-depressant drugs attempt to increase the levels of serotonin or norepinephrine. Unfortunately there are now some studies emerging which indicate these current anti-depressants can increase the risk to develop a range of disorders, from kidney problems to cataracts. Generally the risk profiles are low but given the very widespread use of anti-depressants it could constitute a considerable public health cost. Which raises an interesting question: if we place our faith in these statistical analyses then is the government entitled to extract an "pharmaceutical externality tax" to address the health risks and subsequent costs associated with drug side effectss? Yeah, like that'll ever happen. We'll develop a new class of anti-depressants, and wait 30 years before we know about the associated risks ... .
My unalloyed cynicism aside, what caught my interest about this research is the reference to RGS proteins. It reminded me I read in 1999:
Article:
Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function
Journal: NATURE MEDICINE • VOLUME 5 • NUMBER 8 • AUGUST 1999
Subscribe to:
Posts (Atom)